GLP-1 receptor agonists (e.g., Wegovy, Ozempic, Mounjaro, Saxenda) are increasingly used for weight management and diabetes, including in patients who have had bariatric surgery. However, there are important considerations regarding safety, effectiveness, and interactions with eating behaviors that must be addressed.

Bariatric surgery, such as gastric bypass, sleeve gastrectomy, or lap-band procedures, is often considered for individuals with obesity-related health concerns. However, when eating disorders (EDs) are present or untreated, bariatric treatment comes with significant risks, psychological challenges, and potential worsening of disordered eating behaviors.

In 2023, the American Academy of Pediatrics (AAP) released updated guidelines on the treatment of children and adolescents with overweight and obesity — the first major update in 15 years. These new recommendations have generated a great deal of discussion — especially among pediatricians, therapists, dietitians, and parents of children in larger bodies.